tradingkey.logo

Moderna Says It Presents Promising Early Data For Investigational Cancer Antigen Therapy

ReutersOct 12, 2025 10:08 PM

- Moderna Inc MRNA.O:

  • MODERNA: PRESENTS PROMISING EARLY DATA FOR INVESTIGATIONAL CANCER ANTIGEN THERAPY

  • MODERNA: MRNA-4359 IN COMBINATION WITH PEMBROLIZUMAB SHOWED CONSISTENTLY MANAGEABLE SAFETY PROFILE, NO NEW IMMUNE-RELATED ADVERSE EVENTS

  • MODERNA: MRNA-4359 HAS ADVANCED INTO PHASE 2 PORTION OF ONGOING PHASE 1/2 TRIAL

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI